In an attempt to develop novel targeted anticancer agents, a series of novel substituted phthalazine derivatives has been designed and synthesized as inhibitors of vascular endothelial growth factor receptor (VEGFR) kinase enzyme in accordance to SAR studies of known VEGFR inhibitors. The designed compounds incorporated a biarylamide or biarylurea tail linked to a phthalazine scaffold via an amino or ether linkage or else incorporated an N-substituted piperazine motif at position 1 of the phthalazine core. The prepared compounds were evaluated for their enzymatic inhibition of VEGFR-2 kinase. Furthermore, three of the phthalazines bearing a biarylurea (6b, 6e &7b) exhibited excellent broad spectrum cell growth inhibition against NCI full 60 cell panel with GI 50 values between 0.15-5μM. In addition, docking studies were performed through docking of the investigated compounds into VEGFR-2 binding site in order to gain further insight into their binding affinities and binding interactions with the VEGFR-2 kinase.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.